Reference list
1. WHO List of Prequalified Medicinal Products. Available at: http://apps.who.int/prequal/
(Accessed Aug 2009)
2. Abdulla S, Sagara I, Borrmann S et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 2008; 372:1819-27.
3. van Vugt M, Wilairatana P, Gemperli B et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999; 60: 936-942.
4. van Vugt M, Looareesuwan S, Wilairatana P, et al. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg 2000; 94: 545-548.
5. Lefèvre G, Looareesuwan S, Treeprasertsuk S, et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001; 64: 247-256.
6. Hatz C, Soto J, Nothdurft HD, et al. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in non-immune populations: a safety, efficacy and pharmacokinetic study. Am J Trop Med Hyg 2008; 78: 241-247.
7. Falade C, Makanga M, Premji Z, et al. Efficacy and safety of artemether-lumefantrine (Coartem®) tablets (six-dose regimen) in African infants and children with acute, uncomplicated malaria. Trans R Soc Trop Med Hyg 2005; 99: 459-467.
8. Barnes KI, Durrheim DN, Little F. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu–Natal, South Africa. PLoS Medicine 2005; 2 (11): e330.
9. Chizema-Kawesha E, Mukonka V, Mwanza M et al. Evidence of substantial nationwide reduction of malaria cases and deaths due to scale-up of malaria control activities in Zambia, 2001–2008. World Health Organization, Zambia 19–23 January. Impact Evaluation Mission Report.
10. Novartis Data on File
11. WHO World Malaria Report 2008. Available at: http://who.int/malaria/wmr2008
(Accessed September 2009)
12. WHO Malaria Factsheet No. 94 Updated January 2009. Available at: http://www.who.int/mediacentre/factsheets/fs094/en/index.html
(Accessed September 2009)
13. Roll Back Malaria Partnership. Africa Malaria Report - 2003. Chapter 2: Insecticide-treated nets. Available at: http://rbm.who.int/amd2003/amr2003/pdf/ch2.pdf
(Accessed September 2009)
14. Vestergaard LS and Ringwald P. Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies. Am J Trop Med Hyg 2007; 77: 153-159.
15. The use of antimalarial drugs. World Health Organization. Available at: http://rbm.who.int/cmc_upload/0/000/014/923/am_1.htm (Accessed Aug 2009)
16. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002; 2: 209-218.
17. Roll Back Malaria Partnership. Africa Malaria Report - 2003. Chapter 3: Prompt and effective treatment. Available at: http://www.who.int/malaria/amd2003/amr2003/pdf/ch3.pdf
(Accessed September 2009)
18. World Health Organization News Release 19 January 2006. Available at:
http://www.who.int/mediacentre/news/releases/2006/pr02/en/index.html
(Accessed August 2009.)
19. Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa – a six country study. PLoS ONE 2008; 3(5): e2132 Available at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0002132
(Accessed September 2009)
20. WHO Guidelines for The Treatment of Malaria 2006. Available at: http://apps.who.int/malaria/docs/TreatmentGuidelines2006.pdf
(Accessed August 2009)
21. Roll Back Malaria Partnership. Malaria Landscape Report 2007. Available at: http://rbm.who.int/partnership/board/meetings/docs/Malaria_Landscape_Report_2007.pdf (Accessed September 2009)
22. WHO Model List of Essential Medicines. Available at: http://www.who.int/medicines/publications/08_ENGLISH_indexFINAL_EML15.pdf
(Accessed September 2009)
23. WHO Model List of Essential Medicines for Children. Available at:
http://www.who.int/childmedicines/publications/EMLc%20(2).pdf.
(Accessed September 2009)
24. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999; 37: 105-125.
25. Makanga M, Premji Z, Falade C, et al. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg 2006; 74: 991-998.
26. Sutherland CJ, Ord R, Dunyo S, et al. Reduction in malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Medicine 2005; 2: 0338-0346.
27. Bukirwa H, Yeka A, Kamya MR et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials 2006; 1: e7.
28. Dorsey G, Staedke S, Clark TD et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children. JAMA 2007; 297: 2210-2219.
29. Gürkov R, Eshetu T, Miranda IB et al. Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar J 2008; 7: 179.
30. Kabanywanyi AM, Mwita A, Sumari D, et al. Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania. Malar J 2007; 6: 146.
31. Kamya MR, Yeka A, Bukirwa H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2007; 2: e20.
32. Mårtensson A ,Strömberg J, Sisowath C, et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 2005; 41: 1079-1087.
33. Mårtensson A, Ngasala B, Ursing J et al. Influence of consecutive-day blood sampling on polymerase chain reaction–adjusted parasitological cure rates in an antimalarial-drug trial conducted in Tanzania. J Infect Dis 2007; 195: 597-601.
34. Mohamed AO, Eltaib EH, Ahmed OA, et al. The efficacies of artesunate-sulfadoxine-pyrimethamine and artemether-lumefantrine in the treatment of uncomplicated, Plasmodium falciparum malaria, in an area of low transmission in central Sudan. Ann Trop Med Parasitol 2006; 100: 5-10.
35. Mukhtar EA, Gadalla NB, El-zaki S-EG, et al. A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan. Malar J 2007; 6:92.
36. Mutabingwa TK, Anthony D, Heller A et al. Amodiaquine alone, amodiaquine + sulfadoxinepyrimethamine, amodiaquine + artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005; 365: 1474-1480.
37. Piola P, Fogg C, Bajunirwe F et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 2005; 365: 1467-1473.
38. Yeka A, Dorsey G, Kamya MR et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS ONE 2008; 3:e2390.
39. Mulenga M, Van geertruyden J-P, Mwananyanda L, et al. Safety and efficacy of lumefantrine-artemether (Coartem®) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults. Malar J 2006; 5: 73.
40. Toovey S. Effectiveness of co-artemether in an unsupervised outpatient setting for the treatment of falciparum malaria. Travel Med Infect Dis 2008; 6: 29-31.
41. Adjei GO, Kurtzhals JA, Rodrigues OP et al. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J 2008; 7: 127.
42. Falade CO, Ogundele AO, Yusuf BO, et al. High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Trop Med Int Health 2008; 13: 635-643.
43. Koram KA, Abuaku B, Duah N, Quashie N. Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. Acta Tropica 2005; 95: 194-203.
44. Meremikwu M, Alaribe A, Ejemot R, et al. Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial. Malar J 2006; 5: 43.
45. Owusu-Agyei S, Asante KP, Owusu R, et al. An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and Artemether-Lumefantrine for the treatment of uncomplicated malaria. PLoS ONE. 2008; 3: e2530.
46. Sagara I, Dicko A, Djimde A et al. A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg 2006; 75: 630-636.
47. Sowunmi A, Gbotosho GO, Happi CT et al. Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. Am J Trop Med Hyg 2007; 77: 235-241.
48. Sutherland CJ, Ord R, Dunyo S et al. Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med 2005; 2: e92.
49. Zongo I, Dorsey G, Rouamba N, et al. Artemether-lumefantrine versus amodiaquine plus sulfadoxinepyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 2007; 369: 491-498.
50. Fanello CI, Karema C, van Doren W, et al. A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem®) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. Trans R Soc Trop Med Hyg 2007; 101: 344-350.
51. Guthmann J-P, Cohuet S, Rigutto C, et al. Short report: high efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola. Am J Trop Med Hyg 2006; 75: 143-145.
52. Ndayiragije A, Niyungeko D, Karenzo J, et al. Efficacité de combinaisons thérapeutiques avec des dérivés de l’artémisinine dans le traitement de l’accès palustre non-complique au Burundi. Trop Med Int Health 2004; 9: 673-679.
53. van den Broek I, Kitz C, Al Attas S, et al. Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo. Malar J 2006; 5:113.
54. Haque R, Thriemer K, Wang Z et al. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh. Am J Trop Med Hyg 2007; 76: 39-41.
55. Hutagalung R, Paiphun L, Ashley EA, et al. A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Malar J 2005; 4: 46
56. Krudsood S, Chalermrut K, Pengruksa C, et al. Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP®) and artemether-lumefantrine (Coartem®/Riamet®) in the treatment of acute uncomplicated falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health 2003; 34: 316-321.
57. Mayxay M, Khanthavong M, Lindegårdh N, et al. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People’s Democratic Republic. Clin Infect Dis 2004; 39: 1139-1147.
58. Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007;369:757-765.
59. Rojanawatsirivej C, Vijaykadga S, Amklad I, et al. Monitoring the therapeutic efficacy of antimalarials against uncomplicated falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health 2003; 34: 536-541.
60. Stohrer JM, Dittrich S, Thongpaseuth V, et al. Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People’s Democratic Republic. Trop Med Int Health 2004; 9: 1175-1183.
61. Thapa S, Hollander J, Linehan M, et al. Comparison of artemether-lumefantrine with sulfadoxinepyrimethamine for the treatment of uncomplicated falciparum malaria in Eastern Nepal. Am J Trop Med Hyg 207; 77: 423-430.
62. van den Broek IV, Maung UA, Peters A, et al. Efficacy of chloroquine + sulfadoxine-pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh. Trans R Soc Trop Med Hyg 2005; 99: 727-
735.
63. Woodrow CJ, Haynes RK, Krishna S. Artemisinins. Postgrad Med J 2005; 81: 71-78.
64. Novartis Data on file
65. Mulenga M, Van geertruyden J-P, Mwananyanda L, et al. Safety and efficacy of lumefantrine-artemether (Coartem®) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults. Malaria Journal 2006; 5: 73-84.
66. Roll Back Malaria Partnership. Artemisinin-based combination therapy in Zambia: from policy change to implementation. Available at: http://rbm.who.int/docs/zambia_act_deploying.pdf
(Accessed September 2009)
67. Central Board of Health, Zambia. NMCC (2000) National Malaria Situation Analysis. Zambia. Available at:
http://www.cboh.gov.zm/documents/Copy of Final Malaria SA Document 2000.pdf (Accessed September 2009)
68. Health, a key to prosperity. Success stories in developing countries. WHO website. Available at: http://www.who.int/inf-new/mala3.htm
(Accessed September 2009)
